News
FDA ends 7-year obesity drug drought, clearing Novo Nordisk'...
Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicine
